Zacks Research Estimates Hologic's Q3 Earnings (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Analysts at Zacks Research lowered their Q3 2025 earnings estimates for Hologic in a research note issued on Wednesday, May 21st. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $1.05 per share for the quarter, down from their previous forecast of $1.08. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic's Q4 2025 earnings at $1.08 EPS, FY2025 earnings at $4.20 EPS, Q1 2026 earnings at $1.05 EPS, Q2 2026 earnings at $1.07 EPS, Q3 2026 earnings at $1.11 EPS, Q4 2026 earnings at $1.16 EPS, FY2026 earnings at $4.39 EPS, Q1 2027 earnings at $1.13 EPS, Q2 2027 earnings at $1.18 EPS and FY2027 earnings at $4.80 EPS.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter last year, the business posted $1.03 earnings per share. The company's revenue for the quarter was down 1.2% on a year-over-year basis.

HOLX has been the subject of a number of other research reports. Evercore ISI cut their price objective on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Royal Bank of Canada dropped their target price on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. William Blair reiterated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Finally, Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Twelve research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Hologic presently has a consensus rating of "Hold" and an average target price of $77.42.

Hologic Price Performance

HOLX traded up $1.83 during midday trading on Friday, hitting $64.00. The stock had a trading volume of 4,617,005 shares, compared to its average volume of 2,224,425. Hologic has a 1 year low of $51.90 and a 1 year high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The business has a fifty day moving average of $58.05 and a 200 day moving average of $66.23. The company has a market cap of $14.26 billion, a P/E ratio of 20.27, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54.

Institutional Investors Weigh In On Hologic

A number of institutional investors have recently modified their holdings of HOLX. IFM Investors Pty Ltd boosted its holdings in shares of Hologic by 5.8% during the 1st quarter. IFM Investors Pty Ltd now owns 52,969 shares of the medical equipment provider's stock valued at $3,272,000 after acquiring an additional 2,884 shares during the last quarter. Woodline Partners LP boosted its holdings in Hologic by 2.4% in the first quarter. Woodline Partners LP now owns 147,485 shares of the medical equipment provider's stock worth $9,110,000 after purchasing an additional 3,413 shares during the last quarter. Empowered Funds LLC grew its position in Hologic by 27.7% in the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider's stock worth $1,081,000 after purchasing an additional 3,790 shares during the period. MBB Public Markets I LLC purchased a new stake in Hologic during the 1st quarter valued at $320,000. Finally, United Services Automobile Association bought a new position in shares of Hologic during the 1st quarter valued at $347,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Hologic

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.88% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.